CORALVILLE, IA – 13 September 2012 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, is proud to host Professor Stephen Bustin from Anglia Ruskin University, Cambridge and Chelmsford, for a webinar entitled MIQE Guidelines: A Roadmap for Proper qPCR Experimental Design and Reporting on Tuesday 25th September 2012 at 7am CDT (1pm BST), repeated at 1pm CDT (7pm BST). Professor Stephen Bustin, who led the international consortium that drew up the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines (2009), will discuss approaches to ensure that results reported from today’s most widely used molecular technology are robust, accurate, reliable and complete.
Attendees will hear how the ease with which qPCR data can now be generated sometimes conceals experimental practices that result in the publication of inconsistent, inaccurate or simply wrong results. Incomplete reporting of experimental detail often further confounds assessment of qPCR data validity, calling into question scientific conclusions. Professor Bustin will explain how the MIQE guidelines provide researchers with a blueprint for reliable qPCR experimental design, as well as recommendations to ensure comprehensive reporting of technical detail.
Professor Bustin is in constant demand as a speaker and teacher at international qPCR meetings and workshops, having written the “A-Z of Quantitative PCR” (2004), universally acknowledged as the “qPCR Bible” and more recently “The PCR Revolution” (2011). Register now to attend the webinar.
IDT offers a range of informative and educational webinars, all of which are hosted online. Check them out in IDT’s TechVault. For further information about IDT and its portfolio of primers, probes and PrimeTime® qPCR assays, visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; and Leuven, Belgium. For more information visit www.idtdna.com.
Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)